Background: Esophageal cancers present a significant burden of disease and remain one of the most lethal of cancers worldwide, particular in China. Surgical treatment remains the cornerstone of esophageal cancers, and a real-world data from a high-volume esophageal cancer center have guiding significance in evaluation of the current clinical practice. This report describes the clinical characteristics, treatment outcomes, and survival of surgical treatment in patients with esophageal cancer in Shanghai Chest Hospital (SCH).
Methods: All patients diagnosed with esophageal cancer who received esophagectomy or endoscopic resection at SCH in 2016 were included in this study. The baseline characteristics, treatment-related outcomes, and follow-up data were collated from the medical records and a prospectively maintained database. The clinicopathological characteristics, surgical complications, and oncologic outcomes were summarized. Kaplan-Meier method was used to estimate their survival and Cox regression model was used to estimate the associated risk factors.
Results: In 2016, a total of 546 patients with esophageal cancer received surgical or endoscopic resection at SCH (including 517 esophagectomies and 29 endoscopic resections). Most patients (52.4%) were between 60-69 years old, 79.5% were male, and for more than half of all patients (51.3%), the tumor was located at the middle thoracic esophagus. Overall, 11.0% (60/546) of patients received neoadjuvant therapy and 45.8% (250/546) of patients were treated with adjuvant therapy. Minimally invasive esophagectomy (including thoracoscopy and robot-assisted) was performed in 58.0% of patients and the R0 resection rate was 90.3%. The postoperative 30- and 90-day mortality was 0.73% and 1.1%, respectively. For the esophagectomy cohort, the 1-, 2-, 3-, 4-, and 5-year overall survival (OS) rates were 86.5%, 67.8%, 59.9%, 54.5%, 51.8%, and for cancer specific survival (CSS), the rates were 91.8%, 74.2%, 66.6%, 61.2%, and 59.1%, respectively.
Conclusions: Through a standardized surgical procedure, the short- and long-term outcomes of patients with esophageal cancer were acceptable with good safety and oncological control in a high-volume center in China. This study reveals important surgical treatment effects of esophageal cancer patients and contributes to improvement of clinical management and future treatment development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840046 | PMC |
http://dx.doi.org/10.21037/jtd-22-1672 | DOI Listing |
Clin Transl Gastroenterol
January 2025
Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Background: Lugol's chromoendoscopy (LCE) is valuable, cost-effective, and widely used in early esophageal cancer (EEC) screening, yet it suffers from low compliance due to adverse events after LCE. In addition, the reflux of iodine during iodine staining in the upper esophagus brings the risk of bucking and aspiration. We introduced a new model called distance countdown (DC) aimed to reduce reflux during iodine staining in upper esophageal LCE.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Neoadjuvant chemoimmunotherapy (NCIT) has improved pathological complete response and conferred survival benefits in patients with locally advanced esophageal cancer. However, surgical complications unrelated to the tumor continue to detract from patient outcomes. While the "watch-and-wait" strategy has been implemented in clinical complete responders following neoadjuvant therapy for rectal cancer, there is a lack of evidence supporting its practicability in esophageal cancer after NCIT.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: The role of cancer-associated pericytes (CAPs) in tumor microenvironment (TME) suggests that they are potential targets for cancer treatment. The mechanism of CAP heterogeneity in esophageal squamous cell carcinoma (ESCC) remains unclear, which has limited the development of treatments for tumors through CAPs. Therefore, a comprehensive understanding of the classification, function, cellular communication and spatial distribution of CAP subpopulations in ESCC is urgently needed.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.
Introduction: Esophageal squamous cell carcinoma (ESCC) accounts for 80% of esophageal cancer (EC) worldwide. The molecular characteristics of locally advanced ESCC have been extensively studied.
Methods: In this study, we investigate the genomic and transcriptomic characteristics and try to provide the basic T-cell receptors (TCRs) dynamics and its genomic and transcriptome association during the radiochemotherapy of ESCC using multi-omics analysis.
iScience
January 2025
Department of Oncology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003 Henan, China.
Esophageal carcinoma (EC) is one of the most common malignant tumors in the world. ECRG4 has been recently discovered to be downregulated in EC. However, the mechanism leading to reduced expression of ECRG4 in esophageal cancer remains obscure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!